Weight-loss medications and their effects on anorectal health in severe obesity
Part of Digestive system, Heart & circulation, Hormones & metabolism clinical trials.
This study looks at how new GLP-1 weight-loss medications affect the health of the anus and rectum in people with severe obesity. It may help doctors understand if these medicines improve or worsen early anorectal issues.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 18 years old.
- You must have morbid obesity, which means a BMI of 40 or higher, or a BMI of 35 or higher with health problems like diabetes or high blood pressure.
- You must be newly starting on a GLP-1 medication (like Wegovy, Ozempic, or Mounjaro) for weight loss or diabetes.
- You must be willing to give written consent and come back for a check-up after 3 months.
- You cannot have certain bowel conditions, recent anorectal surgery, or be pregnant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether a newer class of weight-loss medicines (GLP-1 and GIP/GLP-1 analogues) can help people with excess body weight eat healthier and improve their metabolism and behavior. It may be a good option if you are an adult with overweight or obesity and haven't used these medicines recently.
This study tests a new oral medication called ACCG-2671 to see how safe it is and how your body handles it. It's an early-stage trial, so the main focus is on safety and tolerability. The study has different parts: one for people with normal weight and one for people with higher weight who are already taking a GLP-1 injection for weight loss.
This trial tests whether adding a GLP-1 receptor agonist (a medicine used for diabetes and weight loss) to standard chemo-radiation before surgery can improve outcomes for overweight patients with rectal cancer. It aims to see if the medication helps shrink the tumor and improves treatment response.
This study looks at how weight-loss treatments affect pelvic floor symptoms (like bladder or bowel issues) in women with obesity. It may help you understand how your weight-loss journey impacts your pelvic health.
This trial tests a weight-loss medication (GLP-1 receptor agonist) combined with dietary protein to see if it helps protect muscle while losing fat. It is for adults with obesity who are not taking certain other medications or supplements.
This study looks at how GLP-1 receptor agonist drugs (used for weight loss) affect muscle mass and strength in people with obesity who do not have diabetes. It may help understand if these medications impact muscle health.
Hear when a new Anorectal Diseases trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.